Bupropion ( DrugBank: Bupropion )
5 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
8 | ハンチントン病 | 1 |
18 | 脊髄小脳変性症(多系統萎縮症を除く。) | 1 |
21 | ミトコンドリア病 | 1 |
96 | クローン病 | 1 |
171 | ウィルソン病 | 1 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01914965 (ClinicalTrials.gov) | June 2012 | 31/7/2013 | Apathy Cure Through Bupropion in Huntington's Disease | A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease | Apathy;Huntington's Disease | Drug: Bupropion;Drug: Placebo | Charite University, Berlin, Germany | University of Ulm;Ruhr University of Bochum;University Hospital Muenster | Completed | 25 Years | 75 Years | Both | 40 | Phase 2 | Germany |
18. 脊髄小脳変性症(多系統萎縮症を除く。)
臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01716221 (ClinicalTrials.gov) | October 2012 | 25/10/2012 | An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia | An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia | Friedreich Ataxia | Drug: bupropion & Citalopram;Drug: Bupropion & Placebo;Drug: Placebo & Citalopram;Drug: Placebo & Placebo | University of Colorado, Denver | NULL | Completed | N/A | N/A | Female | 1 | Phase 4 | NULL |
21. ミトコンドリア病
臨床試験数 : 39 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04643249 (ClinicalTrials.gov) | November 10, 2020 | 13/11/2020 | Drug-drug Interaction Study of KL1333 in Healthy Subjects | A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects | Mitochondrial Disease | Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide | Abliva AB | NULL | Completed | 18 Years | 65 Years | All | 14 | Phase 1 | United Kingdom |
96. クローン病
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00126373 (ClinicalTrials.gov) | May 2005 | 2/8/2005 | A Trial of Wellbutrin for Crohn's Disease | A Randomized Controlled Trial of Wellbutrin for Crohn's Disease | Crohn Disease | Drug: Wellbutrin (bupropion) | Altschuler, Eric, M.D. | GlaxoSmithKline | Completed | 18 Years | N/A | Both | 1 | Phase 2/Phase 3 | United States |
171. ウィルソン病
臨床試験数 : 79 / 薬物数 : 77 - (DrugBank : 17) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 30
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04526210 (ClinicalTrials.gov) | October 21, 2020 | 19/8/2020 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | Wilson Disease | Drug: ALXN1840;Drug: Bupropion Hydrochloride | Alexion Pharmaceuticals | NULL | Completed | 18 Years | 50 Years | All | 54 | Phase 1 | United States |